Key points are not available for this paper at this time.
Cervical cancer (CC) ranks as the second most common cause of cancer-related deaths among women aged 20-39, resulting in ten premature deaths weekly. CC affects women worldwide as the most common form of genital cancer, with approximately 500,000 new cases diagnosed annually. Besides the risk of death, CC can lead to increased morbidity, causing symptoms like pain, haemorrhage, and kidney failure. These complications pose significant challenges to treatment, particularly in areas with limited healthcare access. Immune dysregulation and chronic inflammation further contribute to CC pathogenesis, creating a pro-carcinogenic microenvironment through immune cell recruitment, cytokine release, and inflammatory responses triggered by persistent HPV infection. Moreover, understanding the socio-economic determinants influencing the prevalence of CC and promoting awareness can contribute to effective public health interventions. Research endeavours in these domains are vital to reduce the burden of CC, enhance early detection, and ultimately save lives. This review covers recent research on CC global epidemiology, intricate pathogenesis insights, protein-based HPV vaccines, and diverse treatment modalities, including recurrent cases. Molecular markers indicating prognosis and the role of artificial intelligence. The review will briefly highlight preventive strategies, offering a comprehensive overview of crucial research areas in CC.
Bhargava et al. (Fri,) studied this question.